Jiménez-Uscanga RD, Ordóñez-Gutiérrez EA, Jiménez-Urueta PS, Gómez-Guillermoprieto L

Language: Spanish
References: 9
Page: 274-280
PDF size: 479.65 Kb.

ABSTRACT

Introduction. Neonatal diabetes mellitus, is a genetic disorder associated with alteration in the number or function of pancreatic cells. The average age of diagnosis is six weeks, and before 6 months of age. It’s diagnosis before three months of age justifies the designation of permanent neonatal diabetes (PND). Transient neonatal diabetes (TND) resolves around 12 weeks. We present a patient with neonatal diabetes mellitus followed for several years.
Report of the case. An 11 year old female presented her first symptoms at 28 days of life with hyperthermia, polyuria, dehydration, and ketoacidosis; she was born at 36 weeks gestation; she weighed 2 Kg at birth and 18.11 in height.
Discussion: Neonatal diabetes mellitus, is a genetic disorder associated with a mutation of chromosome 6q24. Transient neonatal diabetes (TND) resolves spontaneously around 12 weeks of age.
Treatment with insulin gives dramatic results in normal growth, over several weeks or months.

REFERENCES

1. Sperling MA. ATP-Sentive Potassium Channels – Neonatal diabetes mellitus and beyond. N Eng J 2006;355(5):507-10.

2. Flanagan SE, Patch AM, Mackay D, Edghill EL, Gloyn AL, Robinson D. Mutations in ATP-sensitive K channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 2007;56:1930-7.

3. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes. New clinical syndromes. New scientific insights, and new therapy. Diabetes 2005;54:2503-13.

4. Gach A, Wika C, Malecki MT, Noczynska A, Skupien J, Nazim J. Islet-specific antibody seroconversion in patients with long duration of permanent neonatal diabetes caused by mutations in the KCNJ11 gene. Diabetes Care 2007;30:2080-2.

5. Proks P, Girard C, Bævre H, Njølstad PR, Ashcroft FM. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy. Diabetes 2006;55:1731-7.

6. Vaxillaire M, Dechaume A, Busiah K, Cave H, Pereira S, Scharfmann R. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 2007; 56:1737-41.

7. Mankouri J, Taneja TK, Smith AJ, Ponnambalam S, Sivaprasadarao A. Kir6.2 mutations causing neonatal diabetes prevent endocytosis of ATP-sensitive potassium channels. EMBO J 2006; 25:4142–51.

8. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. PNAS 2004;101(50):17539-44.

9. Ewan R, Pearson y cols. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir 6.2 mutations. N Eng J Med 2006; 355(5):467-77.